Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock: Insider Peter Greenleaf Sells 797 Shares

Key Points

• Director Peter Greenleaf sold 797 Pelthos Therapeutics shares at an average price of $21.17, receiving $16,872.49. The transaction was made under a pre-arranged Rule 10b5-1 plan and reduced his ownership by 3.34% to 23,087 shares.
• Pelthos reported a quarterly loss of $6.62 per share on $15.60 million in revenue, with analysts forecasting a full-year loss of $15.22 per share. The stock recently traded at $21.48, well below its 12-month high of $37.50.
• Analyst sentiment remains favorable, with five Buy ratings and one Hold rating producing a “Moderate Buy” consensus and an average price target of $55.40. Institutional investors own approximately 77.96% of the company.

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) Director Peter Greenleaf sold 797 shares of the company's stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $21.17, for a total value of $16,872.49. Following the completion of the sale, the director owned 23,087 shares of the company's stock, valued at $488,751.79. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Price Performance

NYSEAMERICAN PTHS traded up $0.98 on Tuesday, reaching $21.48. 42,943 shares of the stock traded hands, compared to its average volume of 30,248. Pelthos Therapeutics Inc. has a 12 month low of $18.19 and a 12 month high of $37.50. The company has a market cap of $82.27 million, a price-to-earnings ratio of -0.98 and a beta of 3.07. The firm's fifty day simple moving average is $24.74 and its 200 day simple moving average is $25.21. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40.

Pelthos Therapeutics (NYSEAMERICAN:PTHS - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) earnings per share for the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. The firm had revenue of $15.60 million during the quarter. As a group, research analysts predict that Pelthos Therapeutics Inc. will post -15.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Oppenheimer cut their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an "outperform" rating for the company in a report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Pelthos Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $55.40.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE grew its stake in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Free Report) by 59.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 12,919 shares of the company's stock after acquiring an additional 4,819 shares during the period. Pale Fire Capital SE owned about 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 77.96% of the company's stock.

About Pelthos Therapeutics

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company's work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company's specific product pipeline, operating history, geographic reach and leadership is limited.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.